DRUG ATI001-102 A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma

Project: Research project

Project Details

StatusFinished
Effective start/end date10/29/14 → 4/30/22

Funding

  • ZIOPHARM Oncology, Inc. (ATI001-102)